scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Sold by J. Goldman & Co LP

J. Goldman & Co LP cut its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 11.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,219,127 shares of the company's stock after selling 160,866 shares during the period. J. Goldman & Co LP owned about 2.44% of scPharmaceuticals worth $4,316,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Legato Capital Management LLC purchased a new position in scPharmaceuticals during the 4th quarter worth $37,000. China Universal Asset Management Co. Ltd. purchased a new position in scPharmaceuticals during the 4th quarter worth $38,000. Price T Rowe Associates Inc. MD purchased a new position in scPharmaceuticals during the 4th quarter worth $54,000. Wells Fargo & Company MN increased its holdings in shares of scPharmaceuticals by 110.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock valued at $65,000 after purchasing an additional 9,663 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of scPharmaceuticals in the fourth quarter valued at about $66,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Maxim Group dropped their target price on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Stock Up 28.6%

NASDAQ SCPH traded up $0.64 during trading on Thursday, reaching $2.88. 1,691,242 shares of the company's stock were exchanged, compared to its average volume of 365,257. The stock has a market cap of $144.82 million, a P/E ratio of -1.52 and a beta of 0.17. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The company has a 50 day moving average price of $2.60 and a two-hundred day moving average price of $3.19. scPharmaceuticals Inc. has a 1 year low of $1.94 and a 1 year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The business had revenue of $11.75 million for the quarter, compared to analysts' expectations of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, equities research analysts anticipate that scPharmaceuticals Inc. will post -1.53 EPS for the current fiscal year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.